6 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 4 with minor changes only.
Primary completion pushed from Apr 10, 2026 to Dec 2, 2026
Also in this update: Study completion pushed from May 3, 2026 to Dec 2, 2026
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 1 NCT07455084 Registry history of NCT07455084 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 1 NCT07649265 Registry history of NCT07649265 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Otsuka Medical Devices Co., Ltd. JapanPhase 2/3 NCT06589505 Registry history of NCT06589505 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Otsuka Pharmaceutical Factory, Inc.Phase 1 NCT07848334 Registry history of NCT07848334 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3 NCT06894212 Registry history of NCT06894212 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 6 locations
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3 NCT07759128 Registry history of NCT07759128 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-06 | NCT07861113 A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With… | Phase 2 | Not Yet Recruiting |
| 2026-09-30 | NCT07848334 First-in-Human Safety and Tolerability Study of OPF-110 in Healthy Adults | Phase 1 | Active, Not Recruiting |
| Phase 1 | 8 | |
| Phase 1/2 | 2 | |
| Phase 2 | 3 | |
| Phase 2/3 | 4 | |
| Phase 3 | 17 |
ADHD (5) · Schizophrenia (4) · Anxiety (3) · Lupus (SLE) (3) · Atopic Dermatitis (2) · Heart Disease (2) · Alzheimer's Disease (1) · Dementia (1) · Diabetes (1) · Heart Failure (1)